Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Panamera Holdings Corporation (PHCI)
USD2.50
+0.00 (+0.00%)
US OTC Healthcare Medical - Care Facilities
Address
4180 Orchard Hill Drive 77002
Edmond, OK, US
Edmond, OK, US
CEO
T. Benjamin Jennings
Website
panamerahealth.com
IPO
2021-04-21
CIK 1620749 ISIN US69829Y1091
Description
Panamera Holdings Corporation currently lacks substantial ongoing business activities. Historically, the company's focus was on providing management and consulting services within the healthcare sector. Looking ahead, its strategic intent is to identify and capitalize on new business ventures. These opportunities are primarily targeted within the environmental services industry, burgeoning innovative technologies, and integrated health solutions emphasizing individual choice and innovation. The firm adopted its current name, Panamera Holdings Corporation, in October 2021, having previously operated as Panamera Healthcare Corporation. Established in 2014, the company maintains its headquarters in Houston, Texas.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD2.50
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
155
Beta
4.91
Float Shares
13.33M
Free Float %
18.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -42.00% | -63.75% | -65.88% | -59.83% | -35.41% | +28.89% | +16.00% | +1,833.33% | +1,833.33% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
2.50
Quality scores
Altman Z-Score
-6,062.77
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
1 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Care Facilities: +10.2%+1,129.1% ★ Q1'26: +255.6% (vs Q1'25)
-
EPS growth Medical - Care Facilities: +19.2%+96.9% ★ Q1'26: +22.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%-232.6% Q1'26: -16.4% (vs Q1'25)
-
EBIT margin Medical - Care Facilities: +11.3%-220.3% Q1'26: -56.4% (vs Q1'25)
-
ROIC Medical - Care Facilities: +6.8%-85.9% Q1'26: +7.7% (vs Q1'25)
-
Share dilution Medical - Care Facilities: +0.0%+14.0% Q1'26: +62.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×-0.15× Q1'26: -0.19× (vs Q1'25)
Valuation Multiples
From
To
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-641.6K
OE per share TTM
-0.01
Owner's Yield
-0.30%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
41.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
1
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | T Benjamin Jennings | 23.22M | 59.00% | 23.22M | — | 23.22M | — | IN | United States | 2021-06-16 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
50.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+50,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-12 | JENNINGS T BENJAMIN | Director / Officer / 10% Owner | M-Exempt | D | Common Stock | 4,100,000 | 0.01 | 41.0K | 19,120,000 | D | ↗ |
| 2025-10-06 | Proler Cristopher Bryan | Director / Officer | G-Gift | D | Common Stock | 50,000 | 0.01 | 500.00 | 3,316,000 | D | ↗ |
| 2025-02-07 | Proler Cristopher Bryan | Director / Officer | S-Sale | D | Common Stock | 24,000 | 0.50 | 12.0K | 3,316,000 | D | ↗ |
| 2025-01-22 | Proler Cristopher Bryan | Director / Officer | S-Sale | D | Common Stock | 29,000 | 0.29 | 8.4K | 0 | D | ↗ |
| 2024-11-06 | Proler Cristopher Bryan | Director / Officer | S-Sale | D | Common Stock | 200,000 | 0.50 | 100.0K | 3,820,000 | D | ↗ |
| 2024-09-01 | Proler Cristopher Bryan | Director / Officer | G-Gift | D | Common Stock | 10,000 | 0.01 | 100.00 | 3,820,000 | D | ↗ |
| 2024-07-25 | Proler Cristopher Bryan | Director / Officer | S-Sale | D | Common Stock | 150,000 | 0.33 | 49.5K | 3,820,000 | D | ↗ |
| 2024-07-24 | Proler Cristopher Bryan | Director / Officer | S-Sale | D | Common Stock | 100,000 | 0.25 | 25.0K | 4,200,000 | D | ↗ |
| 2024-07-17 | Proler Cristopher Bryan | Director / Officer | G-Gift | D | Common Stock | 300,000 | 0.01 | 3.0K | 4,200,000 | D | ↗ |
| 2024-06-09 | Proler Cristopher Bryan | Director / Officer | S-Sale | D | Common Stock | 100,000 | 0.50 | 50.0K | 4,200,000 | D | ↗ |
| 2023-07-17 | Barakat Christopher | Director | A-Award | A | Common | 1,000,000 | 0.00 | 1.0K | 1,000,000 | — | ↗ |
| 2023-07-10 | WILSON STANLEY F | Director | A-Award | A | Common | 1,000,000 | 0.00 | 1.0K | 1,000,000 | — | ↗ |
| 2022-12-15 | SUMMERS CURTIS EUGENE | Director | P-Purchase | D | Common Stock | 4,330,000 | 0.00 | — | 4,330,000 | — | ↗ |
| 2022-12-15 | BAKER DOUGLAS GLENN | Director | P-Purchase | D | Common Stock | 1,670,000 | 0.00 | — | 1,670,000 | — | ↗ |
| 2021-05-12 | WILSON STANLEY F | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-05-12 | SUMMERS CURTIS EUGENE | Director / 10% Owner | P-Purchase | D | Common Stock | 1,000,000 | 0.03 | 25.0K | 8,660,000 | — | ↗ |
| 2021-05-12 | JENNINGS T BENJAMIN | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 23,220,000 | — | ↗ |
| 2021-05-12 | Barakat Christopher | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-05-12 | BAKER DOUGLAS GLENN | Director / Officer | P-Purchase | D | Common Stock | 1,000,000 | 0.03 | 25.0K | 3,340,000 | — | ↗ |
| 2017-07-31 | SUMMERS CURTIS EUGENE | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-07-31 | DIAZ ERNEST JOSEPH | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-07-31 | BAKER DOUGLAS GLENN | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-05-21 | SUMMERS CURTIS EUGENE | Director / Officer / 10% Owner | — | D | Common Shares | 0 | 0.00 | — | 6,440,000 | — | ↗ |
| 2014-05-21 | DIAZ ERNEST JOSEPH | Director / 10% Owner | — | D | Common Shares | 0 | 0.00 | — | 6,440,000 | — | ↗ |
| 2014-05-21 | BAKER DOUGLAS GLENN | Director / Officer | — | D | Common Shares | 0 | 0.00 | — | 1,120,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-1.8K
Shares Outstanding
73.89M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Cristopher Proler | President & Director | 200.0K | male |
| T. Benjamin Jennings | President & Non-Executive Chairman | 92.3K | male |
| Christopher N. Barakat | Clinical Business Development Officer & Director | 56.0K | male |
| Douglas Glenn Baker | Chief Financial Officer, Secretary, Treasurer & Director | 12.0K | male |
| Jeffrey Carl Kilgore | Executive Officer | — | — |
| Juan Juarez | Senior Vice President of Finance | — | male |
ESG Rating
ESG Score History MEDICAL - CARE FACILITIES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PHCI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
